Nephrogenic systemic fibrosis: Late skin manifestations

Archives of Dermatology

Volumn 145, Issue 2, 2009, Pages 183-187

  Bangsgaard, Nannie ^a   Marckmann, Peter ^a,b   Rossen, Kristian ^a   Skov, Lone ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GADODIAMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; PRIORITY JOURNAL; QUALITY OF LIFE INDEX; SKIN MANIFESTATION;

ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; PEPTIDE FRAGMENTS; PROCOLLAGEN; QUALITY OF LIFE; SKIN DISEASES;

EID: 60349106558     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2008.551     Document Type: Article

References (28)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBroit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356(9234):1000-1001.
2. Marckmann P. Nephrogenic systemic fibrosis: epidemiology update. Curr Opin Nephrol Hypertens. 2008;17(3):315-319.
3. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum. 2006;35(4):238-249.
4. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139(7):903-906.
5. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21(4):1104-1108.
6. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17(9):2359-2362.
7. Khurana A, Runge VM, Narayana M, Greene JF, Nickel AE. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol. 2007;42(2):139-145.
8. Moreno-Romero JA, Segura S, Mascaró JM Jr, et al. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. Br J Dermatol. 2007;157(4):783-787.
9. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging. 2007;26(5):1198-1203.
10. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56(1):21-26.
11. Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging. 2007;2(4):199-205.
12. Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol. 2008;158(2):273-280.
13. Marckmann P, Skov L, Rossen K, Thomsen HS. Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis. Clin Nephrol. 2008;69(3):161-168.
14. Khurram M, Skov L, Rossen K, Thomsen HS, Marckmann P. Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients. Scand J Urol Nephrol. 2007;41(6):565-566.
15. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22(11):3174-3178.
16. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43(2):141-144.
17. Mazzotti E, Picardi A, Sampogna F, Sera F, Pasquini P, Abeni D; IDI Multipurpose Psoriasis Research on Vital Experimental Experiences Study Group. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol. 2003;149(2):318-322.
18. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216.
19. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes. 2003;1:53. doi:10.1186/1477-7525-1-53.
20. Katugampola RP, Hongbo Y, Finlay AY. Clinical management decisions are related to the impact of psoriasis on patient-rated quality of life. Br J Dermatol. 2005;152(6):1256-1262.
21. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23(5):383-393.
22. Glaich AS, Martinelli PT, Markus RF, Hsu S. Generalized elastolysis following nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2005;53(1):174-176.
23. Cokonis Georgakis CD, Falasca G, Georgakis A, Heymann WR. Scleromyxedema. Clin Dermatol. 2006;24(6):493-497.
24. Frei A, Zimmerman A, Weigand K. The N-terminal propeptide of collagen III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. Hepatology. 1984;4(5):830-834.
25. Guseva NG, Anikina NV, Myllyla R, et al. Markers of collagen and basement membrane metabolism in sera of patients with progressive systemic sclerosis. Ann Rheum Dis. 1991;50(7):481-486.
26. Boffa MJ, Smith A, Chalmers RJ, et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol. 1996;135(4):538-544.
27. Soylemezoglu O, Wild G, Dalley AJ, et al. Urinary and serum type III collagen: markers of renal fibrosis. Nephrol Dial Transplant. 1997;12(9):1883-1889.
28. Honkanen E, Fröseth B, Grönhagen-Riska C. Serum hyaluronic acid and procollagen III amino terminal propeptide in chronic renal failure. Am J Nephrol. 1991;11(3):201-206.